

# Scott M Wasserman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484611/publications.pdf>

Version: 2024-02-01

9  
papers

5,660  
citations

1307594

7  
h-index

1588992

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

6794  
citing authors

#	ARTICLE	IF	CITATIONS
1	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. American Journal of Preventive Cardiology, 2020, 3, 100091.	3.0	2
2	Effect of Evolocumab on Coronary Plaque Composition. Journal of the American College of Cardiology, 2018, 72, 2012-2021.	2.8	95
3	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722.	27.0	4,179
4	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. Circulation, 2017, 135, 338-351.	1.6	80
5	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 633-643.	27.0	366
6	Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". Circulation, 2017, 136, 120-121.	1.6	0
7	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). American Heart Journal, 2016, 176, 83-92.	2.7	45
8	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. JAMA - Journal of the American Medical Association, 2016, 316, 2373.	7.4	813
9	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. Circulation Research, 2015, 117, 731-741.	4.5	80